These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibition of in vitro tumor cell proliferation by cytokines induced by combinations of TLR or TLR and TCR agonists. Ghosh TK; Mickelson DJ; Lipson KE; Alkan SS Int Immunopharmacol; 2007 Nov; 7(11):1471-82. PubMed ID: 17761351 [TBL] [Abstract][Full Text] [Related]
4. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Roses RE; Xu M; Koski GK; Czerniecki BJ Oncogene; 2008 Jan; 27(2):200-7. PubMed ID: 18176601 [TBL] [Abstract][Full Text] [Related]
5. TLR signaling by tumor and immune cells: a double-edged sword. Huang B; Zhao J; Unkeless JC; Feng ZH; Xiong H Oncogene; 2008 Jan; 27(2):218-24. PubMed ID: 18176603 [TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Spaner DE; Masellis A Leukemia; 2007 Jan; 21(1):53-60. PubMed ID: 17066089 [TBL] [Abstract][Full Text] [Related]
7. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Lahiri A; Das P; Chakravortty D Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576 [TBL] [Abstract][Full Text] [Related]
12. Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. Chen R; Alvero AB; Silasi DA; Steffensen KD; Mor G Oncogene; 2008 Jan; 27(2):225-33. PubMed ID: 18176604 [TBL] [Abstract][Full Text] [Related]
13. Expression and function of toll-like receptors at the maternal-fetal interface. Koga K; Mor G Reprod Sci; 2008 Apr; 15(3):231-42. PubMed ID: 18421019 [TBL] [Abstract][Full Text] [Related]
14. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. de Vos AF; Pater JM; van den Pangaart PS; de Kruif MD; van 't Veer C; van der Poll T J Immunol; 2009 Jul; 183(1):533-42. PubMed ID: 19542464 [TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor and RIG-I-like receptor signaling. Kawai T; Akira S Ann N Y Acad Sci; 2008 Nov; 1143():1-20. PubMed ID: 19076341 [TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Krieg AM Oncogene; 2008 Jan; 27(2):161-7. PubMed ID: 18176597 [TBL] [Abstract][Full Text] [Related]
17. Phosphatase PTP1B negatively regulates MyD88- and TRIF-dependent proinflammatory cytokine and type I interferon production in TLR-triggered macrophages. Xu H; An H; Hou J; Han C; Wang P; Yu Y; Cao X Mol Immunol; 2008 Aug; 45(13):3545-52. PubMed ID: 18571728 [TBL] [Abstract][Full Text] [Related]
18. Toll-like receptors and innate immunity. Kumar H; Kawai T; Akira S Biochem Biophys Res Commun; 2009 Oct; 388(4):621-5. PubMed ID: 19686699 [TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors and their role in hematologic malignancies. Wolska A; Lech-Maranda E; Robak T Curr Mol Med; 2009 Apr; 9(3):324-35. PubMed ID: 19355914 [TBL] [Abstract][Full Text] [Related]
20. Primer: Toll-like receptor signaling pathways--what do rheumatologists need to know? O'Neill LA Nat Clin Pract Rheumatol; 2008 Jun; 4(6):319-27. PubMed ID: 18446139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]